TNGX · Tango Therapeutics

The thesis

Tango Therapeutics' pancreatic-cancer combination is active, but the shares are more likely to lag the S&P 500 over three months. The 23 October 2026 European Society for Medical Oncology (ESMO) update, 82% response in 22 patients against 92% in 12 in June, did not extend the June result. A confirmed start of the front-line Phase 3 trial, targeted for the first half of 2027, settles whether the development path holds.

The third-quarter report, filed 9 November 2026, showed cash, cash equivalents and marketable securities of $977.5 million at 30 September 2026 and a net loss of $68.4 million, or $0.39 per share (company results release). Wall Street analysts expected a loss of $0.35 per share. The company still plans a global, randomized Phase 3 of vopimetostat plus Revolution Medicines' daraxonrasib against standard chemotherapy, with response rate and progression-free survival as dual primary endpoints.

The shares recovered from a $20.87 close on 5 November 2026 to $25.73 on 11 November 2026 and closed at $24.85 on 12 November 2026. That is below the $27.93 close of 22 October 2026, the session before the ESMO data (IBTimes).

Bullish and bearish views on Tango Therapeutics, Inc.

The bull case on Tango Therapeutics, Inc. (TNGX), in brief: the combination remains highly active. The bear case: the headline response rate fell.

Bull case

• The combination remains highly active. 18 of 22 evaluable patients with MTAP-deleted, RAS-mutant pancreatic cancer responded, and 88% were progression-free at nine months, with median progression-free survival not reached (pharmaphorum, 23 October 2026).
• The Phase 3 design is defined. The 9 November 2026 results release describes a global trial against chemotherapy in front-line MTAP-deleted pancreatic cancer, starting in the first half of 2027 after FDA discussions, with overall survival as a key secondary endpoint.
• Cash funds the plan. The company held $977.5 million at 30 September 2026 and says it covers its current operating plan (company results release, 9 November 2026).
• Analysts stayed positive after the report. On 10 November 2026 JPMorgan kept Overweight and raised its target to $47, Wedbush kept Outperform and lowered its target to $40, and H.C. Wainwright kept Buy and lowered its target to $67.
• A second combination is enrolling. Tango and Erasca announced on 4 November 2026 that a Phase 1/2 trial of vopimetostat plus ERAS-0015 in pancreatic and lung cancer has opened enrollment.

Bear case

• The headline response rate fell. The 82% rate in 22 patients compares with 92% in 12 in June. The shares fell about 16% to $23.40 early on 23 October 2026 on volume above 3.8 million shares (IBTimes).
• Spending is rising. Third-quarter research and development expense was $48.9 million against $30.8 million a year earlier, and general and administrative expense was $29.2 million against $8.9 million, which the company tied partly to share-based compensation for former executive officers (results release, 9 November 2026). Collaboration revenue was zero.
• Stock supply is available at any time. A prospectus supplement filed 11 August 2026 allows up to $400 million of at-the-market sales without notice. Weighted-average shares were 173,930,255 in the third quarter, up from 168,380,091 shares outstanding reported in the second-quarter 10-Q.
• Insiders keep selling. President of R&D Adam Crystal sold 5,000 shares at an average $22.42 and Principal Accounting Officer Jessica Newcomb sold 7,031 shares at an average $22.42 on 2 November 2026, both under Rule 10b5-1 plans (SEC Form 4, filed 4 November 2026).
• The partner controls the key drug. Revolution Medicines owns daraxonrasib, its supply and its registrational trials. Daraxonrasib is also active alone, so the combination data do not isolate vopimetostat's contribution.
• Dose tolerability is narrow. The 200 mg daily dose was generally well tolerated in 30 patients, while 250 mg was not (pharmaphorum, 23 October 2026).

Price setup

The shares closed at $24.85 on 12 November 2026, above the 50-day average of $23.47 and the 200-day average of $22.83. The three-month change is –2.9%, against a close of $25.60 on 14 August 2026.

The close sits 27.7% below the 52-week high of $34.39, reached intraday on 17 June 2026. The 52-week closing low is $7.67, set on 12 November 2025.

The path since the results: $21.50 on 6 November 2026, $22.74 on 9 November 2026, $24.30 on 10 November 2026, $25.73 on 11 November 2026, then $24.85 on 12 November 2026. The shares have regained most of the ground lost after ESMO but not the $27.93 close that preceded it. The price reflects a dataset that is active but not larger or stronger than June, plus a defined Phase 3 plan with a first-half 2027 start.

Catalysts ahead

• ~30 June 2027 (est.): End of the first half of 2027, the company's target window for the front-line Phase 3 start. A confirmed trial start is the main remaining test of the development path; a slip would weaken the case.

What would change the view

A daily close above $32.90, the highest close of the last 126 sessions (15 June 2026), which would show the shares leading the S&P 500 again. A Phase 3 first-patient start announced ahead of the first-half 2027 window would point the same way.

What it trades with

Tango trades on its own clinical news and on Revolution Medicines' daraxonrasib program, which supplies the combination partner drug. Both move with sentiment toward clinical-stage oncology companies. The 23 October 2026 fall of about 16% on data that were active but not better than June shows how much of the earlier rise rested on expectations for the larger dataset.